Johns Hopkins School of Medicine

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Retrieved on: 
Thursday, November 9, 2023
Patient, Clinical trial, Health, Crave, Psychiatry, MEAI, Safety, Depression, Johns Hopkins School of Medicine, AUD, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.

Key Points: 
  • The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
  • Johns Hopkins University School of Medicine is the second US-based medical site to join the Company’s clinical trial.
  • The potential of psychedelic drugs to treat various neuropsychiatric indications is currently being explored in multiple human clinical trials.

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 8, 2023
Data Management, Other Health, Technology, Pharmaceutical, Oncology, General Health, Hospitals, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, NSCLC, GBM, DHL, Mantle cell lymphoma, Artificial intelligence, BBB, Lung, Rituximab, IO, USD, AI, Starlight, Lung cancer, Liver, Permeability, Antibody, Cancer, Machine learning, Pancreatic cancer, Brain, NHL, Safety, Therapy, Liquid biopsy, Patient, D, Central nervous system, DNA, Automation, ATM, Johns Hopkins School of Medicine, PD-1, Spacecraft, Fox Chase Cancer Center, MCL, Society, Education, Incidence, Patent, Bone marrow, Harmonic, CNS, Drug development, PDX, Algorithm, Breast, Glioblastoma, Metadata, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Cryptocurrency, Lantern

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter ended September 30, 2023.
  • Lantern plans to release additional details and data on this set of results with LP-284 in this setting in the coming month.
  • G&A Expenses: General and administrative expenses were approximately $1.3 million for the quarter ended September 30, 2023, compared to approximately $1.4 million for the quarter ended September 30, 2022.
  • Earnings Call and Webinar Details:
    Lantern will host its third quarter 2023 earnings call and webinar today, November 8, 2023, at 4:30 p.m.

Dr. Ephraim Fuchs Joins ImmunoFree, Inc. as its Chief Medical Officer

Retrieved on: 
Tuesday, November 7, 2023
Science, Johns Hopkins School of Medicine, National Kidney Registry, Johns Hopkins, Oncology, Doctor of Philosophy, MBA, NYU, Clinical trial, Business, University, W. P. Carey School of Business, Cancer, CMO, Patient, Immunosuppression, Dentistry, MD

GREENWICH, Conn., Nov. 7, 2023 /PRNewswire/ -- Today, ImmunoFree , Inc. announced that Dr. Ephraim Fuchs has been appointed the Chief Medical Officer of ImmunoFree.

Key Points: 
  • GREENWICH, Conn., Nov. 7, 2023 /PRNewswire/ -- Today, ImmunoFree , Inc. announced that Dr. Ephraim Fuchs has been appointed the Chief Medical Officer of ImmunoFree.
  • Dr. Fuchs is a Co-founder of ImmunoFree and Professor of Oncology & Immunology at the Johns Hopkins University School of Medicine.
  • This same procedure forms the foundation for all successful kidney transplant tolerance protocols for unrelated donor-recipient pairs.
  • "We are thrilled to have Dr. Fuchs join the ImmunoFree executive team as our Chief Medical Officer," said Garet Hil, Co-Founder & CEO of ImmunoFree, Founder & CEO of the National Kidney Registry, living kidney donor and the father of a kidney transplant recipient.

77-Year-Old Professional Racecar Driver Shares Life Lessons Learned in the Fast Lane in Inspiring and Purposeful New Memoir

Retrieved on: 
Tuesday, November 7, 2023
Data analysis, International, Life, Johns Hopkins School of Medicine, Publishing, Ferrari Challenge, Multimedia, Nelson Ledges Road Course, IMSA, Ferrari, Team, Cancer, Barnes & Noble, Entertainment, Daytona, Amazon, Giovani (footballer, born 2004)

For professional racecar driver Ted Giovanis, it's also where you can learn the most valuable lessons.

Key Points: 
  • For professional racecar driver Ted Giovanis, it's also where you can learn the most valuable lessons.
  • After nearly three decades in the driver's seat, Giovanis has divulged his most valuable wisdom in the new book Focus Forward: Life Lessons from Racing, published today by Amplify Publishing.
  • Ted Giovanis, previously a veteran of the healthcare industry, began his professional career in 2006, at the age of 61.
  • He shows you how the tools of racing and the teamwork within it are applicable to life and business.

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Retrieved on: 
Friday, November 3, 2023
Johns Hopkins School of Medicine, Therapy, Liver, MD, CHB, Poster, Late, KOL, Hepatitis, Patient, Liver disease, SAN, Pharmaceutical industry, Medicine

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, to review the Late Breaking results and next steps for ALG-000184, its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB), and the unmet need and current treatment landscape for patients with CHB on November 16, 2023 at 1:30 PM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, to review the Late Breaking results and next steps for ALG-000184, its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB), and the unmet need and current treatment landscape for patients with CHB on November 16, 2023 at 1:30 PM ET.
  • To register, click here.
  • The Phase 1 data are being featured being featured in a late breaking poster session at the Liver Meeting® of the American Association of Liver Disease on November 13, 2023 (poster #5028-C).
  • A live question and answer will follow the formal presentation.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit

Retrieved on: 
Friday, November 3, 2023
Drug development, Type, AD, Dermatology, Eosinophilic bronchitis, Duke University, Johns Hopkins School of Medicine, Mortality, Cytokine, CCL3, Research, Inflammation, DDDS, Dupilumab, Research fellow, Biology, Constriction, ASLN, Chemokine, Head, AHR, Atopic dermatitis, International Society, Patient, Chronic obstructive pulmonary disease, CCL4, SAN, Pharmaceutical industry, COPD

ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.

Key Points: 
  • ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.
  • The model tested airway hyperresponsiveness (AHR) in the lung tissue using IL-4 and IL-13, the key Th2 cytokines involved in COPD disease pathology3.
  • Furthermore, IL-4 and IL-13 sensitized the airways to further constriction in response to methacholine, but this sensitization was blocked by eblasakimab treatment.
  • The presentation from Drug Development Summit can be accessed via the ASLAN website here .

Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)

Retrieved on: 
Thursday, November 2, 2023
Type, FDA, Physical medicine and rehabilitation, Medical Affairs Bureau, Johns Hopkins School of Medicine, Outline of health sciences, Food, Chronic pain, Walter Reed National Military Medical Center, SP-102, Rehabilitation, Physician, Neurology, MD, Injection, Dexamethasone, Psychiatry, PALO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Uniformed Services University of the Health Sciences, Observation, Senior, Behavioural sciences, File, LRP, Anesthesiology, NDA, Pain, Patient, Pharmaceutical industry, Pain management

The Company has reached agreement with the FDA on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (“NDA”).

Key Points: 
  • The Company has reached agreement with the FDA on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (“NDA”).
  • Recently, during the Type C meeting with the FDA, the Company received an advisement on expectations and requirements to file the NDA, including clinical and preclinical data.
  • Scilex intends to file the SP-102 NDA utilizing the 505(b)(2) regulatory pathway to reference the currently approved drug, Dexamethasone sodium phosphate injection.
  • SP-102 (SEMDEXATM) is expected to be administered in up to 3 injections during a 6-month observation period.

Nuwellis Announces Board of Directors Transition

Retrieved on: 
Wednesday, November 1, 2023
Capital market, AARP, Johns Hopkins School of Medicine, RBC Capital Markets, St. Olaf College, Business development, News, Hypervolemia, UnitedHealth Group, Internal medicine, Judgement, Gallup, University of Minnesota Medical School, Seniority (financial), Senior, Growth, Caregiver, Delcath Systems, Carlson School of Management, American Express, Head, University, World Bank, Lake Street, CNN, Patient, Hospital, Mayo Clinic, Nursing, MD, Economics, Medicine

“With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board.

Key Points: 
  • “With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board.
  • Dave’s significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives.
  • In turn, our board will benefit from perspectives gained from Archelle’s healthcare policy, clinical, and patient education experience in bringing medical decisions closer to patients and caregivers,” said Nestor Jaramillo Jr, President and CEO of Nuwellis.
  • In addition, Nuwellis announced that Jon Salveson is stepping down from the Board after 10 years of outstanding service.

Onconova Expands Leadership Team with Two Key Appointments

Retrieved on: 
Tuesday, October 24, 2023
Drug development, Research, Bone marrow, Ovarian cancer, Nottingham Trent University, Medicine, Internal medicine, Bachelor, Biomedical sciences, George Washington School, Pediatric Hematology and Oncology, Medical Affairs Bureau, Pharmacy, European Society for Clinical Investigation, Pharmaceutical medicine, University of Zimbabwe, Postgraduate diploma, Epidermolysis bullosa, University, NDA, Cancer, Therapy, Patient, Myelodysplastic syndrome, Merrimack Pharmaceuticals, GSK plc, Medication, CMO, Nottingham, Johns Hopkins School of Medicine, King's College London, University of Surrey, IND, Consultant, Outline of health sciences, Patent, Rare, Inflammation, R, EB, Johnson & Johnson, Pharmaceutical industry, Nursing, Biotechnology, Science, Hematology, Honours degree

NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D).

Key Points: 
  • Both are accomplished experts in their fields and bring significant and wide expertise in drug development.
  • I look forward to working with my colleagues at Onconova and our clinical collaborators to contribute to our mission of bringing narazaciclib and rigosertib to patients with cancer.
  • He has also held various leadership roles as Vice President of Clinical Investigations at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.
  • Prior to that, she held various leadership roles as Medical Director or Associate Medical Director, as well as roles in Investigator Research and Medical Affairs at Celgene International.

Prevent Blindness Provides Informational Resources to Professionals and the Public for November's Diabetes-related Eye Disease Awareness Month

Retrieved on: 
Wednesday, October 25, 2023
UnitedHealth Group, Social media, Population health, US, American Diabetes Association, Diabetic retinopathy, Prevalence, Health, Mental, Disease, Risk, Eye, Public, Paratriathlon, Potential, Retina, Parent, Mental health, MHS, Yale School of Medicine, Organization, Prediabetes, National Eye Institute, CDC, Centers for Disease Control and Prevention, Vision, VSP Vision Care, Research, JAMA Ophthalmology, Visual impairment, Microsoft PowerPoint, Research to Prevent Blindness, MBA, Database, Johns Hopkins School of Medicine, Associate, Pharmaceutical industry, Ophthalmology, Regeneron Pharmaceuticals, MD, Diabetes

CHICAGO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- A recent study, "Prevalence of Diabetic Retinopathy in the US in 2021," estimated that more than 26 percent of people with diabetes had diabetic retinopathy. Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute.

Key Points: 
  • Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute .
  • The longer a person has diabetes, the greater the risk for diabetes-related eye disease.
  • Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared November as Diabetes-related Eye Disease Awareness Month, providing the public with a variety of helpful tools to prevent unnecessary vision loss from diabetes.
  • Vision Integration Library - The Center for Vision and Population Health at Prevent Blindness offers the free "Vision Integration Library: Vision and Eye Health Resource Center at Prevent Blindness."